BWXT Medical Business Sale
BWXT Sells Medical Business to Nordic Capital for Up to $800 Million, Shifts Focus to Nuclear
Anonymous
BWX Technologies (NYSE: BWXT) is selling its medical business to Nordic Capital in a deal valued at up to $800 million, the company announced. The sale covers BWXT Medical and Kinectrics' stable medical isotopes business, according to National Post.
The move lets BWXT zero in on its core markets: nuclear national security and commercial nuclear power. The deal is expected to close by the end of 2026, pending regulatory approvals, The Whig reported.
BWXT Sheds Medical Arm to Sharpen Nuclear Focus
BWXT has been building a presence in radiopharmaceuticals — drugs that use radioactive materials to treat cancer and other diseases. But the company decided that business sits outside its long-term lane. By selling it, BWXT can put more money and attention into nuclear defense and power work, Edmonton Sun reported.
The deal is not a simple flat fee. The "up to $800 million" figure includes potential earn-outs, meaning BWXT could get more money if the medical business hits certain performance targets after the sale closes, according to Leader Post.
Nordic Capital Brings Deep Radiopharmaceutical Experience
Nordic Capital is not a newcomer to healthcare investing. The firm has a track record in the radiopharmaceutical space, which made it an attractive buyer, The Province reported. Radiopharmaceuticals are a fast-growing field as drugmakers race to develop targeted cancer treatments using radioactive isotopes.
Under Nordic Capital's ownership, the medical business is expected to expand its capabilities and grow its market presence. BWXT said it believes the business is well-positioned to scale, according to Cochrane Times Post.
What BWXT's Medical Business Actually Does
BWXT Medical produces medical isotopes — radioactive atoms used in imaging and cancer treatment. Kinectrics' stable medical isotopes business, also included in the sale, supplies non-radioactive isotopes used in medical research and therapy. Together, they form a niche but valuable slice of the nuclear medicine supply chain, Daily Herald Tribune reported.
Medical isotopes are in high demand globally. Hospitals and cancer centers rely on them for procedures like PET scans and targeted radiation therapy. The market has attracted significant investment in recent years, Hanna Herald noted.
Nuclear Defense and Power Drive BWXT's Future Plans
With the medical unit gone, BWXT plans to accelerate growth in two areas: nuclear national security and commercial nuclear power. Both markets are expanding. The US government is investing heavily in nuclear propulsion for ships and submarines. Commercial nuclear power is also seeing renewed interest as countries look for clean energy sources, according to Fairview Post.
The deal is still subject to regulatory review and is not expected to close until late 2026. Until then, the medical business will continue to operate as part of BWXT, National Post reported.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
9
Articles
9
Reach
9
A
AnonymousAuthor